[Glyvenol: representative of a new type of plurivalent substance class with antiallergic and anti-inflammatory properties].
D000588:Amines / Q000037:antagonists & inhibitors; D000707:Anaphylaxis / Q000188:drug therapy; D000818:Animals; D000893:Anti-Inflammatory Agents; D000917:Antibody Formation / Q000187:drug effects; D001183:Arthus Reaction / Q000188:drug therapy; D001920:Bradykinin / Q000037:antagonists & inhibitors; D003168:Complement Fixation Tests; D004487:Edema / Q000188:drug therapy; D004731:Endotoxins / Q000037:antagonists & inhibitors; D006027:Glycosides; D006099:Granuloma / Q000188:drug therapy; D006168:Guinea Pigs; D006386:Hemagglutination Tests; D006634:Histamine H1 Antagonists; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D010455:Peptides / Q000037:antagonists & inhibitors; D011817:Rabbits; D051381:Rats
D000588:Amines; D000893:Anti-Inflammatory Agents; D004731:Endotoxins; D006027:Glycosides; D006634:Histamine H1 Antagonists; D010455:Peptides; D001920:Bradykinin
Glyvenol: Repräsentant einer neuartigen plurivalenten Substanzklasse mit antiallergischen und antiinflammatorischen Eigenschaften.